SCHEMBL6293754

SCHEMBL6293754

CCOC(=O)C1=C(C2CC2)Nc2n[nH]cc2C1c1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
POLB P06746 1/20 0.48
CYP2C9 P11712 4/20 0.44
CYP3A4 P08684 4/20 0.44
CYP2C19 P33261 3/20 0.44
ALOX12 P18054 1/20 0.44
LMNA P02545 3/20 0.43
ALDH1A1 P00352 2/20 0.43
CACNA1C Q13936 2/20 0.43
CACNA1F O60840 1/20 0.43
CACNA1D Q01668 1/20 0.43
CACNA1S Q13698 1/20 0.43
TBXA2R P21731 3/20 0.43
ADRA1A P35348 3/20 0.43
SLC6A3 Q01959 3/20 0.43
ADORA3 P0DMS8 3/20 0.43
ABCB11 O95342 2/20 0.43
ABCB1 P08183 2/20 0.43
HTR1A P08908 2/20 0.43
ADRA2A P08913 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6292340 0.88 BCHE (0.41) TSHRPOLBALDH1A1CACNA1CCACNA1F
SCHEMBL6296464 0.86 TSHR (0.56) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6293722 0.84 ACHE (0.49) TSHRCYP2C9CYP3A4CYP2C19ALOX12
SCHEMBL6293581 0.84 TBXA2R (0.49) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6293440 0.82 ADORA3 (0.47) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6292316 0.82 TSHR (0.47) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6292289 0.82 TBXA2R (0.48) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6296672 0.82 TSHR (0.47) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6293386 0.81 TBXA2R (0.46) TSHRPOLBCYP2C9CYP3A4CYP2C19
SCHEMBL6293726 0.81 TBXA2R (0.46) TSHRPOLBCYP2C9CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
EP-1355909-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-10-29 EP disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed
WO-2002062795-A2 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB TSHR 4767/4885POLB 3061/4885CYP2C9 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.